Insecticides IndiaQ1 FY24

Insecticides India Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹545.5P/E: 13.0Market Cap: ₹1.6K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Targeting ~20% CAGR revenue growth over the next 5 years (Rajesh Aggarwal, Page 12 and 13).
  • FY 2024 revenue growth expected around 10% to 12%, with Q2 anticipated to be strong (Page 13).
  • Export turnover target initially INR 200 crores, revised to INR 150 crores for FY 2024, with better export numbers expected from September onward (Page 16 and 17).
  • Doubling of company turnover approximately every 5 years, from INR 500 crores in 2012 to near INR 2,000 crores currently (Page 17).
  • Focus on new product launches (4 lined up in Q2), value-added and patented products driving growth (Page 6, 14).
  • Biological products segment poised for meaningful launches starting FY 23-24, expected to contribute incremental revenue (Page 15).
  • Expansion capex of INR 150 crores planned to support capacity for anticipated growth (Page 12).

See what Insecticides India management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No explicit mention of fundraising through debt or equity in the provided transcript.
  • The company has spent around INR25 crores on land acquisition and plans a total capex of about INR150 crores over the next 2 years for expansion (Dahej, Sotanala, SEZ plant).
  • The majority of the capital expenditures appear to be funded internally or from ongoing operations, as there is no specific reference to raising funds externally.
  • Emphasis is on organic growth powered by R&D, registrations, capacity expansions, and product launches, targeting 20% CAGR in revenue over next 5 years.
  • No indications of plans for raising fresh equity or taking on new debt were discussed in the call excerpts.

See what Insecticides India management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Chopanki technical plant capacity increased by ~50%; already in production.
  • Dahej plant to commence production post-Diwali 2023; 95% of expenses done.
  • Acquired ~15 acres land at Sotanala, Rajasthan (Sotanala District, Behror); INR 25 crores spent on acquisition.
  • Planned capex of approx. INR 100 crores over 2 years at Sotanala for formulation, technical synthesis, and possibly biological plant.
  • INR 25 crores planned for SEZ facility expansion (focused on export demand).
  • Another INR 25 crores allocated for routine expansions at Dahej and smaller projects including biologicals.
  • Total planned spend over next 2 years approximately INR 150 crores.
  • Biological plant location decision pending (Chopanki or Sotanala).
  • Focus on new product launches (7–8 products planned for FY '24–'25).
  • Upgraded technology systems: SAP HANA, BI dashboards, CRM with Salesforce for improved customer connectivity and risk mitigation.

Track Insecticides India — get its next earnings analysis in your feed

How does Insecticides India rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisInsecticides India
Rev 3Mar 2

How does Insecticides India rank in Fertilizers & Agrochemicals?

Compare Insecticides India against every Fertilizers & Agrochemicals company (Q1 FY24) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →